Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death

Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

(2013) E. Blackwood et al.   MOLECULAR CANCER THERAPEUTICS

Identification of Preferred Chemotherapeutics for Combining with aCHK1Inhibitor

(2013) Yang Xiao et al.   MOLECULAR CANCER THERAPEUTICS

From yeast to mammals: Recent advances in genetic control of homologous recombination

(2012) Yoav Karpenshif et al.   DNA REPAIR

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

(2012) S Origanti et al.   ONCOGENE

Claspin and Chk1 regulate replication fork stability by different mechanisms

(2011) Jennifer Scorah et al.   CELL CYCLE

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

Integrated Cytogenetic and High-Resolution Array CGH Analysis of Genomic Alterations Associated with MYCN Amplification

(2011) A. Pandita et al.   CYTOGENETIC AND GENOME RESEARCH

Brca2, Rad51 and Mre11: Performing balancing acts on replication forks

(2011) Vincenzo Costanzo   DNA REPAIR

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

(2011) T. J. Guzi et al.   MOLECULAR CANCER THERAPEUTICS

Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01

(2011) K. F. On et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

(2011) R. Montano et al.   MOLECULAR CANCER THERAPEUTICS

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death

(2010) Elizabeth Garner et al.   CELL CYCLE

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

(2010) Di Marco   ONCOLOGY REPORTS

Chk1 promotes replication fork progression by controlling replication initiation

(2010) E. Petermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2

(2009) Joshua L Andersen et al.   EMBO JOURNAL

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe

(2009) Oliver Riesterer et al.   INVESTIGATIONAL NEW DRUGS

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis

(2009) S. Peddibhotla et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors

(2008) Zhan Xiao et al.   BIOMARKERS

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint

(2008) Florian Bassermann et al.   CELL

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins

(2008) J. D. Young et al.   XENOBIOTICA